Market Cap : 11.58 M | Enterprise Value : 11.45 M | PE Ratio : | PB Ratio : |
---|
OTCPK:ICOTF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OTCPK:ICOTF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. iCo Therapeutics's interest expense for the three months ended in Sep. 2020 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2020 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. iCo Therapeutics's Operating Income for the three months ended in Sep. 2020 was $ -0.15 Mil. iCo Therapeutics's Interest Expense for the three months ended in Sep. 2020 was $ 0.00 Mil. iCo Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2020 was 0 (Dec. 2019 ) + 0 (Mar. 2020 ) + 0 (Jun. 2020 ) + 0 (Sep. 2020 ) = $0.00 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
iCo Therapeutics's Interest Expense for the three months ended in Sep. 2020 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2020 was $-0.15 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2020 was $0.00 Mil.
iCo Therapeutics's Interest Coverage for the quarter that ended in Sep. 2020 is calculated as
iCo Therapeutics had no debt. |
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
iCo Therapeutics Inc has no debt.
No Headline